Ultime notizie per Amylyx Pharma (NASDAQ:AMLX) Azioni

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

WIIM

United States Cellular shares are trading higher after the company announced an agreement with AT&T to sell a portion of its retained spectrum licenses for $1.018 billion.

News

Dividends

CCOI

Cogent Communications Raises Dividend From $0.985 To $0.995

PRTH

Priority Technology Holdings shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Turning Point Brands shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its guidance.

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) released its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% drop share price change the following day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data now available, it's crucial to gauge how its competitors, including PubMatic, TechTarget, and National CineMedia, have been performing.</p>
<ul>
<li>PubMatic's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's projected EPS of $-0.02, resulting in a 950.0% increase.</li>
<li>TechTarget's earnings on August 08, 2024 exceeded market projections, revealing an EPS of $0.42 compared to the estimated EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia announced earnings on November 05, 2024, revealing results below market expectations. Despite the market's anticipation of an EPS of $-0.03, National CineMedia's actual EPS was $-0.04, resulting in a -33.33% decrease compared to expectations.</li>
</ul>
<h3>Competitors Quarterly Earnings and Stock Performance Analysis</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Study: Estimated vs. Actual Peer Revenues</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Clear Channel Outdoor Q3 Earnings Assessment

MTSI

MACOM Technology Solutions shares are trading higher after the company reported Q4 EPS in line with estimates and sales that beat expectations.

EPAM

EPAM Systems shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates. Also, the company issued better-than-expected Q4 revenue guidance and Adj. EPS guidance with its midpoint above estimates.

<p>MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $0.20 by 225 percent.  The company reported quarterly sales of $135.466 million which beat the analyst consensus estimate of $135.208 million by 0.19 percent.  This is a 22.86 percent increase over sales of $110.258 million the same period last year.</p>


Earnings Beats

Earnings Misses

MoneyLion Q3 2024 GAAP EPS $(0.25) Misses $0.20 Estimate, Sales $135.466M Beat $135.208M Estimate

Hilton Grand Vacations shares are trading higher after the company reported Q3 EPS in line with estimates and sales that beat expectations.

<p>Compass Point  analyst Dominick Gabriele   upgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Neutral to Buy and raises the price target from $8 to $15.</p>


Upgrades

Price Target

Analyst Ratings

AVDX

Compass Point Upgrades AvidXchange Holdings to Buy, Raises Price Target to $15

General

VERO

Venus Concept Announces Expansion Of International Distribution Network With Index International In Taiwan And Quirugil In Colombia

<p>Needham  analyst Bernie McTernan   reiterates Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Hold.</p>


Reiteration

LYFT

Needham Reiterates Hold on Lyft

<p>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "Company" or "ParaZero"), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircraft, recently announced that it has received a $187,000 purchase order from a U.S.-based Advanced Air Mobility (AAM) company in the aerial vehicle industry. This order, which was initially announced in September 2024, followed the successful completion of the advanced drone safety system customization project that the Company previously announced and marks another milestone for ParaZero in the growing air mobility sector.</p>
<p>The purchase order included preparations for serial production, as well as the delivery of an initial batch of systems, signifying the initiation of potential future large-scale manufacturing and deployment of ParaZero's cutting-edge drone safety solutions. This order also represents the final step in fulfilling the comprehensive project requirements for the client, who has been closely working with ParaZero to ensure the integration of ParaZero's innovative drone safety technologies.</p>
<p>The order followed a customization project that focused on integrating an innovative safety solution into the customer's manned aircrafts, which is designed for personal, private, military and logistical applications.</p>


Contracts

PRZO

ParaZero Secured $187,000 Purchase Order For Cutting-Edge Drone Safety Systems, Moving Closer To Mass-Production

Health Care

Financing

OFIX

Orthofix Medical Announced The Entry Into A New Credit Agreement Providing The Company With Up To $275M In A Senior-secured Term Loan With A 48-month Interest Only Period

<p>Needham  analyst Charles Shi   reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Hold.</p>


Needham Reiterates Hold on ARM Holdings

<p>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) affirms FY2024 Adj EPS guidance from $5.85-6.10 to $5.85-6.10 vs $5.98 analyst estimate..</p>


Guidance

Duke Energy Affirms FY24 Adj EPS Guidance Of $5.85-$6.10 vs $5.98 Est

<p>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.83) by 2.41 percent.</p>


RPTX

Repare Therapeutics Q3 2024 GAAP EPS $(0.81) Beats $(0.83) Estimate, Cash, Cash Equivalents And Marketable Securities Were $179.4M, Expected To Fund Its Current Operational Plans Into The Second Half Of 2026

<p><strong>Fourth-Quarter and Full-Year 2024 Financial Outlook</strong></p>
<p>Guidance metrics are based on continuing operations.</p>
<p>The Company is providing guidance on tax expense due to the expected fluctuation of its quarterly tax rate, stemming from the deferred tax reserve matter previously disclosed in fourth-quarter 2022. Importantly, the reserve does not impact cash taxes. Some portion of the reserve may reverse in future periods.</p>
<p>The Company closed the sale of its U.S. Sheer Hosiery business on September 29, 2023. For the full year 2023, its U.S. Sheer Hosiery business generated $50 million of net sales and an operating loss of $(2) million.</p>
<p>For fiscal year 2024, which ends on December 28, 2024, the Company currently expects:</p>
<ul>
<li>Net sales from continuing operations of approximately $3.61 billion, which includes projected headwinds of approximately $50 million from last year's U.S. Sheer Hosiery divestiture and approximately $42 million from changes in foreign currency exchange rates. This represents an approximate 4% decrease as compared to prior year on a reported basis and an approximate 2% decrease on an organic constant currency basis.</li>
<li>GAAP operating profit from continuing operations of approximately $174 million.</li>
<li>Adjusted operating profit from continuing operations of approximately $417 million, which includes a projected headwind of approximately $8 million from changes in foreign currency exchange rates.</li>
<li>Pretax charges for restructuring and other action-related charges of approximately $243 million.</li>
<li>GAAP and Adjusted Interest expense of approximately $195 million, which reflects the pay down of debt from the use of net proceeds from the <i>Champion</i> sale and internal cash generation.</li>
<li>GAAP Other expenses of approximately $53 million, which includes approximately $10 million of accelerated amortization of debt issuance costs. Adjusted Other expenses of approximately $43 million.</li>
<li>GAAP and Adjusted Tax expense of approximately $40 million, which includes a net tax benefit primarily related to a release of certain tax reserves.</li>
<li>GAAP loss per share from continuing operations of approximately $(0.32).</li>
<li>Adjusted earnings per share from continuing operations of approximately $0.39.</li>
<li>Cash flow from operations of approximately $250 million.</li>
<li>Capital investments of approximately $50 million, consisting of approximately $40 million of capital expenditures and approximately $10 million of cloud computing arrangements. Per GAAP, capital expenditures are reflected in cash from investing activities and certain cloud computing arrangements are reflected in Other Assets within cash flow from operating activities. The approximate $10 million of cloud computing arrangements is factored into the full year cash flow from operations guidance of approximately $250 million.</li>
<li>Free cash flow of approximately $210 million.</li>
<li>Fully diluted shares outstanding of approximately 355 million.</li>
</ul>
<p>For fourth-quarter 2024, which ends on December 28, 2024, the Company currently expects:</p>
<ul>
<li>Net sales from continuing operations of approximately $900 million, which includes projected headwind of approximately $4 million from changes in foreign currency exchange rates. This represents an approximate 2% increase as compared to prior year on a reported basis and an approximate 3% increase on an organic constant currency basis.</li>
<li>GAAP operating profit from continuing operations of approximately $95 million.</li>
<li>Adjusted operating profit from continuing operations of approximately $115 million, which includes a projected headwind of approximately $1 million from changes in foreign currency exchange rates.</li>
<li>Pretax charges for restructuring and other action-related charges of approximately $20 million.</li>
<li>GAAP and Adjusted Interest expense of approximately $45 million, which reflects the pay down of debt from the use of net proceeds from the <i>Champion</i> sale and internal cash generation.</li>
<li>GAAP Other expenses of approximately $24 million, which includes approximately $10 million of accelerated amortization of debt issuance costs. Adjusted Other expenses of approximately $14 million.</li>
<li>GAAP and Adjusted Tax expense of approximately $5 million, which includes a net tax benefit primarily related to a release of certain tax reserves.</li>
<li>GAAP earnings per share from continuing operations of approximately $0.06.</li>
<li>Adjusted earnings per share from continuing operations of approximately $0.14.</li>
<li>Fully diluted shares outstanding of approximately 357 million.</li>
</ul>
<p>HanesBrands has updated its quarterly frequently-asked-questions document, which is available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Hanes.com%2FFAQ&amp;esheet=54148472&amp;newsitemid=20241107569107&amp;lan=en-US&amp;anchor=www.Hanes.com%2FFAQ&amp;index=1&amp;md5=b4b20882990d535ada47fa19da8098bf">www.Hanes.com/FAQ</a>.</p>


Hanesbrands Sees Q4 Adj. EPS $0.14 Vs $0.12 Est.; Net Sales Of ~$900M Vs $942.13M Est.; FY24 Adj. EPS $0.39 Vs $0.34	 Est.; Net Sales Of ~$3.61B Vs $3.6B Est.

Dynatrace shares are trading lower. The company reported Q2 financial results.

<p>XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(1.59) per share which missed the analyst consensus estimate of $(0.44) by 261.36 percent.  The company reported quarterly sales of $9.197 million which beat the analyst consensus estimate of $6.493 million by 41.65 percent.  This is a 1.01K percent increase over sales of $830.000 thousand the same period last year.</p>


XOMA

XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate

Amylyx Pharmaceuticals, Inc. (AMLX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Amylyx Pharmaceuticals, Inc. is poi...

Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility

Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report) ...

Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intra-Cellular Therapies (ITCI – Research Report), Amylyx Pharmac...

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on AMLX stock, giving a Hold rating on October 17. Graig Suvannavej...

Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties

As previously reported, BofA analyst Charlie Yang upgraded Amylyx (AMLX) to Buy from Neutral with a price target of $10, up from $4.20, based on th...

Amylyx upgraded to Buy at BofA on 'underappreciated' PBH opportunity

BofA upgraded Amylyx (AMLX) to Buy from Neutral with a $10 price target Published first on TheFly – the ultimate source for real-time, market-movin...

Amylyx upgraded to Buy from Neutral at BofA

Bank of America Securities analyst Charlie CY Yang maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report) today. The compan...

Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), GlaxoSmithKline (GSK – Research ...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

INGN

INSM

ISRG

ITCI

NMRA

NRGV

VTYX

Press Releases

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Legal

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Comments

Amylyx Pharma

Notizie

Ultime notizie per Amylyx Pharma (NASDAQ:AMLX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO